Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aldioxa, also known as aluminum allantoate, is a mucosal protective agent used for the treatment of gastric ulcers, duodenal ulcers, and gastritis. It is a chemical complex consisting of aluminum and allantoin, designed to provide both protective and healing properties to the gastrointestinal lining. The drug works by forming a protective protein-binding film over ulcerated areas, shielding them from the aggressive effects of gastric acid and pepsin. Furthermore, it stimulates the production of endogenous prostaglandins and gastric mucus, and promotes the formation of granulation tissue to accelerate the repair of damaged mucosa. Aldioxa has been developed and marketed by several companies, including Taisho Pharmaceutical, and is typically administered orally in forms such as granules or tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aldioxa.